EAACI Congress 2025

Back
13 - 16 June 2025 Glasgow, United Kingdom

LP-003 Significantly Decreases CSU Disease Activity and is Well Tolerated: Top Line Results from a Phase 2 Trial

Sunday 15 Jun, 12:45 PM - 12:52 PM Glasgow, United Kingdom